Paul Anderson, CEO of Orthocell, discusses the company's collagen-based medical devices aimed at regenerative medicine. He covers their products for bone regeneration, nerve repair, and tendon repair, highlighting their clinical success and market potential. The conversation also covers the company's strategic partnerships, regulatory approvals, and future plans for expansion, particularly in the U.S. market. Paul emphasizes the company's commitment to manufacturing in Australia. Takeaways - Orthocell specializes in regenerative medicine with a focus on collagen-based products. - The company has developed three main products for bone, nerve, and tendon repair. - Their bone regeneration product is approved in multiple jurisdictions, including the U.S. and Europe. - The nerve repair product aims to improve surgical outcomes by reducing scar tissue. - Clinical trials have shown an 85% success rate in nerve repair surgeries. - The market for their products is estimated to be worth $3.5 billion globally. - Orthocell plans to enter the U.S. market with a 510(k) submission by the end of 2024. - The company has raised $17 million to support its U.S. expansion efforts. - Their manufacturing process is based in Australia, emphasizing local production. - The leadership team includes experienced professionals with strong industry connections. Chapters 00:14 - Overview of Orthocell and Its Products 03:51 - Bone Regeneration Product and Market Potential 06:28 - Nerve Repair Product: Innovation and Benefits 13:44 - Clinical Outcomes and Patient Impact 19:02 - Market Competition and Future Directions 24:13 - Entering the US Market 25:32 - Regulatory Pathways and Approvals 27:14 - Marketing Strategies and Clinical Data 29:50 - Product Differentiation and Competitive Edge 32:05 - Market Sizing and Revenue Potential 34:59 - Pricing Strategy and Economic Benefits 38:18 - Sales Distribution and Partnerships 39:32 - Financial Position and Board Strength 42:41 -Future Milestones and Expectations Keywords Orthocell, regenerative medicine, collagen, nerve repair, medical devices, clinical trials, market strategy, healthcare innovation, product launch, financial growth